Areteia Therapeutics
Closed
Committed to putting asthma patients in better control
- Headquarters
- Chapel Hill, North Carolina
- Employees
- 11–50
- Founded
- 2022
- Business Model
- B2B
- Website
- areteiatx.com
- Total Funding
- $425.0M
- Last Round
- $75.0M Series AFeb 2024
About
Areteia Therapeutics was a clinical-stage biotechnology company developing dexpramipexole, an oral eosinophil-maturation inhibitor, to treat eosinophilic asthma and put patients back in control of their disease. Focused on novel inflammation and immunology therapies, it raised $425M in funding led by ARCH Venture Partners and GV. The company wound down operations in late 2025 amid Phase 3 drug trials.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account